Sein Métastatique SAFIR02 Breast Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer. Paris, Saint-Cloud MARIE PAULE SABLIN
Appareil Digestif AAS-Lynch Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome Paris, Saint-Cloud BRUNO BUECHER
Recherches "plusieurs pathologies" AcSé Nivolumab Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Paris
Gynécologie ASCORDIA01 ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses Paris, Saint-Cloud CAROLINE MALHAIRE, ROMAN ROUZIER
Appareil pulmonaire ATALK - ML39349 An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy Paris NICOLAS GIRARD
Sein Métastatique ATTAIN (NKTR 15-102-14) A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine. Paris, Saint-Cloud
Sein Métastatique BROCADE 3 (M12-914) A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Paris, Saint-Cloud FLORENCE LEREBOURS
Phases précoces tumeurs solides CA009-002 (Immuno) A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy;of anti-GITR Monoclonal Antibody (BMS-986156) Administered Alone and in Combination;with Nivolumab (BMS-936558, anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors Paris EMANUELA ROMANO
Phases précoces tumeurs solides CA017-003 A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors. Paris CHRISTOPHE LE TOURNEAU
Appareil pulmonaire Checkmate 722 (CA209-722) Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy Paris